# Cypherpunk Technologies Inc. (CYPH) fundamentals

Data as of 2026-11-05. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.48, market value $267 million.

## Valuation
- **P/E (trailing): 3.9×** (5-yr avg 16.6×, 3-yr avg 16.6×). Cypherpunk Technologies Inc. trades at 3.9× trailing earnings, well below its own five-year average of 16.6×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 178.2×**. Each dollar of revenue is priced at 178.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 25.4%**. The inverse of the P/E: 25.4% of the price is earned each year.

## Profitability
- **Return on equity: 3.1%**. 3.1% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: -24.9%**. Each dollar of assets produces -24.9% of profit.

## Growth
- **EPS growth (1 yr): 103.9%**. Earnings per share rose 103.9%.

## Financial health
- **Current ratio: 35.56** (quick 35.56). Current assets cover the next year's liabilities 35.56 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Cypherpunk Technologies Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 588.2%** (YTD 147.4%, 3-mo 291.5%). The shares are up 588.2% over twelve months including dividends.
- **From 52-week high: -40.8%** (531.0% above the low). Trading 41% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 4.97** (volatility 409%). Beta of 4.97 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CYPH · Page: https://foliofundamentals.com/stocks/cyph

Not investment advice.